Despite hundreds of potential therapies for COVID-19 seeking to make their case, very few have crossed the finish line. One graduate candidate, Regeneron’s two-antibody cocktail, has earned early plaudits – and now a pharmaceutical giant is jumping on board to boost production in a big way. Regeneron will partner with …
Read More »